These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance. Cubeddu LX Am Heart J; 1988 Jul; 116(1 Pt 1):133-62. PubMed ID: 2899387 [TBL] [Abstract][Full Text] [Related]
3. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Itskovitz HD Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316 [TBL] [Abstract][Full Text] [Related]
4. The hemodynamic effects of adrenergic blocking agents. Lund-Johansen P Cleve Clin J Med; 1992; 59(2):193-200. PubMed ID: 1350235 [TBL] [Abstract][Full Text] [Related]
5. The place of alpha blockers in the treatment of hypertension. Reid JL Clin Exp Hypertens; 1993 Nov; 15(6):1291-7. PubMed ID: 7903577 [TBL] [Abstract][Full Text] [Related]
6. The cardiovascular effects of alpha-receptor blocking agents. Leren P J Hypertens Suppl; 1992 Jun; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110 [TBL] [Abstract][Full Text] [Related]
7. Evolution of the clinical management of hypertension. Emerging role of "specific" vasodilators as initial therapy. Dzau VJ Am J Med; 1987 Jan; 82(1A):36-43. PubMed ID: 2879462 [TBL] [Abstract][Full Text] [Related]
8. New perspectives on selective alpha 1 blockade. Luther RR Am J Hypertens; 1989 Sep; 2(9):729-35. PubMed ID: 2572243 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. Weidinger G Arzneimittelforschung; 1995 Nov; 45(11):1166-71. PubMed ID: 8929232 [TBL] [Abstract][Full Text] [Related]
10. Clinical implications of pathophysiologic changes in the midlife hypertensive patient. Julius S Am Heart J; 1991 Sep; 122(3 Pt 2):886-91. PubMed ID: 1678918 [TBL] [Abstract][Full Text] [Related]
12. Antihypertensive therapy in the geriatric patient: II. A review of the alpha1-adrenergic blocking agents. Studer JA; Piepho RW J Clin Pharmacol; 1993 Jan; 33(1):2-13. PubMed ID: 8094084 [TBL] [Abstract][Full Text] [Related]
13. Role of selective alpha 1 blockers in the therapy of hypertension. Kaplan NM Am J Med; 1986 May; 80(5B):100-4. PubMed ID: 2872800 [TBL] [Abstract][Full Text] [Related]
14. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Lowe FC Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685 [TBL] [Abstract][Full Text] [Related]
15. Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism. Nash DT Clin Cardiol; 1990 Nov; 13(11):764-72. PubMed ID: 1980236 [TBL] [Abstract][Full Text] [Related]
16. Pharmacology of combined alpha-beta-blockade. I. Louis WJ; McNeil JJ; Drummer OH Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889 [TBL] [Abstract][Full Text] [Related]
17. Alpha blockers: a reassessment of their role in therapy. Cauffield JS; Gums JG; Curry RW Am Fam Physician; 1996 Jul; 54(1):263-6, 269-70. PubMed ID: 8677841 [TBL] [Abstract][Full Text] [Related]
18. Alpha- and beta-receptor blocking drugs in the treatment of hypertension. Ram CV; Kaplan NM Curr Probl Cardiol; 1979 Jan; 3(10):1-53. PubMed ID: 40755 [TBL] [Abstract][Full Text] [Related]
19. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol. Lund-Johansen P Drugs; 1984; 28 Suppl 2():35-50. PubMed ID: 6151890 [TBL] [Abstract][Full Text] [Related]